|Bid||1.2700 x 334700|
|Ask||1.2750 x 1317400|
|Day's range||1.2700 - 1.3250|
|52-week range||1.0150 - 2.5200|
|Beta (5Y monthly)||1.30|
|PE ratio (TTM)||N/A|
|Earnings date||24 Aug 2021 - 30 Aug 2021|
|Forward dividend & yield||N/A (N/A)|
|Ex-dividend date||25 Mar 1988|
|1y target est||1.44|
Starpharma today announced new data demonstrating that SPL7013, the antiviral agent in VIRALEZE™ nasal spray, is active against the highly transmissible Delta variant of SARS-CoV-2, achieving more than 99.99% reduction of infectious virus in laboratory-based virucidal assays.
The makers of a nasal spray claim it's more than 99 per cent effective against the COVID-19 Delta variant sweeping the world, while the product has not had approval from Australian authorities.Melbourne-based biopharmaceutical group Starpharma on Tuesday published test results to show its Viraleze spray, already used in Europe and India, works well against the highly infectious Delta.
The last three months have been tough on Starpharma Holdings Limited ( ASX:SPL ) shareholders, who have seen the share...